Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1965 1
1966 2
1967 2
1971 1
1972 2
1973 3
1974 1
1975 1
1976 1
1978 2
1979 2
1980 2
1981 1
1983 1
1984 1
1985 1
1987 2
1990 1
1999 1
2000 4
2001 4
2003 3
2004 7
2006 3
2007 10
2008 3
2009 4
2010 10
2011 13
2012 14
2013 5
2014 10
2015 10
2016 10
2017 16
2018 18
2019 11
2020 20
2021 26
2022 28
2023 17
2024 22
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

274 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L. Chu Q, et al. Among authors: grosso f. Lancet. 2023 Dec 16;402(10419):2295-2306. doi: 10.1016/S0140-6736(23)01613-6. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931632 Clinical Trial.
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, Chitnis M, Roy A, Gilligan D, Kindler H, Papadatos-Pastos D, Ceresoli GL, Mansfield AS, Tsao A, O'Byrne KJ, Nowak AK, Steele J, Sheaff M, Shiu CF, Kuo CL, Johnston A, Bomalaski J, Zauderer MG, Fennell DA; ATOMIC-Meso Study Group. Szlosarek PW, et al. Among authors: grosso f. JAMA Oncol. 2024 Apr 1;10(4):475-483. doi: 10.1001/jamaoncol.2023.6789. JAMA Oncol. 2024. PMID: 38358753 Free PMC article. Clinical Trial.
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream.
Calabrò L, Bronte G, Grosso F, Cerbone L, Delmonte A, Nicolini F, Mazza M, Di Giacomo AM, Covre A, Lofiego MF, Crinò L, Maio M. Calabrò L, et al. Among authors: grosso f. Front Immunol. 2024 Jan 8;14:1333661. doi: 10.3389/fimmu.2023.1333661. eCollection 2023. Front Immunol. 2024. PMID: 38259475 Free PMC article. Review.
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL. Pinto C, et al. Among authors: grosso f. Lancet Oncol. 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6. Epub 2021 Sep 6. Lancet Oncol. 2021. PMID: 34499874 Clinical Trial.
Pericardial Mesothelioma, a Disease for Brave Hearts.
Grosso F, Cerbone L, Pasello G. Grosso F, et al. J Thorac Oncol. 2022 Dec;17(12):1333-1334. doi: 10.1016/j.jtho.2022.09.224. J Thorac Oncol. 2022. PMID: 36410967 Free article. No abstract available.
Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling.
Novelli F, Yoshikawa Y, Vitto VAM, Modesti L, Minaai M, Pastorino S, Emi M, Kim JH, Kricek F, Bai F, Onuchic JN, Bononi A, Suarez JS, Tanji M, Favaron C, Zolondick AA, Xu R, Takanishi Y, Wang Z, Sakamoto G, Gaudino G, Grzymski J, Grosso F, Schrump DS, Pass HI, Atanesyan L, Smout J, Savola S, Sarin KY, Abolhassani H, Hammarström L, Pan-Hammarström Q, Giorgi C, Pinton P, Yang H, Carbone M. Novelli F, et al. Among authors: grosso f. Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2405231121. doi: 10.1073/pnas.2405231121. Epub 2024 Jul 11. Proc Natl Acad Sci U S A. 2024. PMID: 38990952 Free PMC article.
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
Piccirillo MC, Chu Q, Bradbury P, Tu W, Coschi CH, Grosso F, Florescu M, Mencoboni M, Goffin JR, Pagano M, Ciardiello F, Cecere FL, Vincent M, Ferrara R, Dawe DE, Hao D, Lee CW, Morabito A, Gridelli C, Cavanna L, Iqbal M, Blais N, Leighl NB, Wheatley-Price P, Tsao MS, Ugo F, El-Osta H, Gargiulo P, Gaudreau PO, Tu D, Sederias J, Brown-Walker P, Perrone F, Seymour L, Laurie SA. Piccirillo MC, et al. Among authors: grosso f. J Thorac Oncol. 2023 Jun;18(6):813-819. doi: 10.1016/j.jtho.2023.02.003. Epub 2023 Feb 24. J Thorac Oncol. 2023. PMID: 36841541 Free article. Clinical Trial.
Theriogenology Question of the Month.
Diehl BN, Hawkins I, Grosso FV, Rae O, Cabrera C. Diehl BN, et al. Among authors: grosso fv. J Am Vet Med Assoc. 2022 Aug 17;260(13):1647-1649. doi: 10.2460/javma.22.08.0340. J Am Vet Med Assoc. 2022. PMID: 35976985 Free article. No abstract available.
274 results